Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125788 · ClinicalTrials.gov registry record · Phase 2
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
A Phase 2 study, sponsored by Emmaus Medical.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00125788 is a Phase 2 study that has completed, run by Emmaus Medical. The registered enrollment target is 70 participants.
The verdict
NCT00125788, a Phase 2 study, has completed, sponsored by Emmaus Medical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.
Interventions
- DRUG Placebo
- DRUG L-glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125788
The ClinicalTrials.gov registry entry for NCT00125788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emmaus Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00125788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125788 about?
NCT00125788 is a clinical study titled "L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia". The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.
What is the current status of trial NCT00125788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00125788?
The interventions under investigation include: Placebo (DRUG), L-glutamine (DRUG).
Who is sponsoring clinical trial NCT00125788?
This trial is sponsored by Emmaus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.